SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : bluebird bio Inc. -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (39)1/10/2014 5:46:01 AM
From: idos  Read Replies (2) | Respond to of 163
 
They might report some initial data from the beta-thalassemia major trials later this year, and on the CCALD, better not hear anything...
On their burn rate - it's true that they don't enroll many patients but the treatment includes expensive steps (myeloablation, stem cell transplantation, ex vivo manufacture for each patient etc).